Sildenafil Use, Body Image Concerns, and Performance Anxiety among Gym-Going Men: A Psychiatric Perspective
Abstract
Recreational use of sildenafil (Viagra) has been rising among young men, particularly fitness enthusiasts. While it is prescribed for erectile dysfunction, its nonmedical use is associated with psychological factors such as body image concerns and sexual performance anxiety.
This study aimed to explore the association between sildenafil use, body image concerns, and sexual performance anxiety in gym-going men.
A cross-sectional and comparative study was conducted among 120 male fitness enthusiasts aged 20–40 years. Participants were divided into two groups: sildenafil users (
n
= 60) and nonusers (
n
= 60). The Body Image Concern Inventory (BICI) and the Sexual Performance Anxiety Scale (SPAS) were administered. Data were analyzed using independent
t
-tests, Chi-square tests, and regression analysis.
Sildenafil users reported significantly higher body image concern scores (
M
= 42.5 ± 8.1) compared to nonusers (
M
= 36.2 ± 7.6;
P
< 0.01). Similarly, sexual performance anxiety was greater among sildenafil users (
M
= 24.8 ± 5.9) compared to nonusers (
M
= 18.7 ± 6.2;
P
< 0.001). Regression analysis indicated that body image concerns significantly predicted sildenafil use (b = 0.41,
P
< 0.01), and sexual performance anxiety mediated this relationship.
Recreational sildenafil use among gym-going men is associated with heightened body image dissatisfaction and sexual performance anxiety. Preventive interventions should address the psychological underpinnings of misuse, promoting…
Read the paper
Related studies
- 2024 update in heart failure
- Vascular involvement in idiopathic pulmonary fibrosis
- A novel technique- subendometrial autologous platelet rich plasma injection in patients with unresponsive thin endometrium undergoing frozen-thawed embryo transfer: a prospective cohort study
- Does metformin prolong pregnancy in preterm pre-eclampsia? A study protocol for a South African, hospital-based double-blind, randomised, placebo-controlled trial
- Combined Pulmonary Fibrosis and Emphysema (CPFE): A "New" Smoking-Related Interstitial Lung Disease (ILD)
- Impact of an acute 1-month cannabidiol treatment on pain and inflammation after a long bone fracture: a triple-blind randomised, placebo-controlled, clinical trial protocol
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.